MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of...
- Mechanism
- Curator reviewed
AGS-PSCA is a high affinity, fully human IgG1k MAb directed to PSCA, generated using XenoMouse technology. PSCA is expressed at significant levels on tumor cells from a majority of patients with all stages of prostate, pancreatic and bladder cancers. Pre-clinical studies utilizing human specimens of these tumors in xenograft mouse models have consistently demonstrated that AGS-PSCA significantly inhibits both tumor growth and metastases. Pre-clinical animal toxicology and pharmacokinetic studies have indicated that all administered doses of AGS-PSCA is well tolerated and demonstrated a long serum half-life.
- Primary indication
- Investigated for use/treatment in prostate cancer.Curator reviewed
- Also known as
- ANTI-PSCA MONOCLONAL ANTIBODY AGS-1C4D4
- Code names
- AGS-1C4D4 · AGS-PSCA · MK-4721
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with MK-4721, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account